Rhus verniciflua stokes against advanced cancer: A perspective from the korean integrative cancer center

48Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Active anticancer molecules have been searched from natural products; many drugs were developed from either natural products or their derivatives following the conventional pharmaceutical paradigm of drug discovery. However, the advances in the knowledge of cancer biology have led to personalized medicine using molecular-targeted agents which create new paradigm. Clinical benefit is dependent on individual biomarker and overall survival is prolonged through cytostatic rather than cytotoxic effects to cancer cell. Therefore, a different approach is needed from the single lead compound screening model based on cytotoxicity. In our experience, the Rhus verniciflua stoke (RVS) extract traditionally used for cancer treatment is beneficial to some advanced cancer patients though it is herbal extract not single compound, and low cytotoxic in vitro. The standardized RVS extract's action mechanisms as well as clinical outcomes are reviewed here. We hope that these preliminary results would stimulate different investigation in natural products from conventional chemicals. Copyright 2012 Woncheol Choi et al.

Cite

CITATION STYLE

APA

Choi, W., Jung, H., Kim, K., Lee, S., Yoon, S., Park, J., … Lee, S. (2012). Rhus verniciflua stokes against advanced cancer: A perspective from the korean integrative cancer center. Journal of Biomedicine and Biotechnology. https://doi.org/10.1155/2012/874276

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free